FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder Psychiatric TimesUS FDA approves at-home…
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally approved…